GLONGHUI, November 18 | Eli Lilly has filed a lawsuit against the US Health Resources and Services Administration (HRSA), accusing it of trying to unreasonably block Eli Lilly's specific discount model for drugs supplied under the government's 340B plan. Earlier, Johnson & Johnson also filed a lawsuit for similar reasons. In a lawsuit filed Thursday in federal court in Washington, D.C., Eli Lilly alleges that HRSA lacked reasonable grounds or procedures to try to block its cash replenishment model for 340B-covered entities. Pharmacists participating in the 340B program are required to provide discounts on expensive outpatient medicines provided by healthcare providers serving uninsured and low-income patients. Eli Lilly's cash supplement model involves making direct weekly cash payments to healthcare providers and aims to prevent abuses in current programs and ensure compliance with existing laws and the new requirements of the Inflation Reduction Act.